A phase 1b/2 proof of concept trial of ODS-101 in cancer patients with severe colitis induced by treatment with immuno checkpoint inhibitors (CUII)
Latest Information Update: 31 Jul 2024
At a glance
- Drugs ODS 101 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; Proof of concept
- 16 Jul 2024 According to an Oncodesign Biotechnology media release, the company plans to start this trial in fourth quarter of 2024 with phase II scheduled to start in 2025.
- 26 Mar 2023 According to an Oncodesign Biotechnology media release, this trial is expected to begin at the end of 2024.
- 20 Feb 2023 New trial record